OBIO vs. BFLY, IRMD, AVNS, BBNX, SIBN, KIDS, TMCI, DCTH, NPCE, and NYXH
Should you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include Butterfly Network (BFLY), Iradimed (IRMD), Avanos Medical (AVNS), Beta Bionics (BBNX), SI-BONE (SIBN), OrthoPediatrics (KIDS), Treace Medical Concepts (TMCI), Delcath Systems (DCTH), NeuroPace (NPCE), and Nyxoah (NYXH). These companies are all part of the "medical equipment" industry.
Orchestra BioMed vs.
Orchestra BioMed (NASDAQ:OBIO) and Butterfly Network (NYSE:BFLY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Orchestra BioMed has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Butterfly Network has a beta of 2.48, suggesting that its stock price is 148% more volatile than the S&P 500.
Orchestra BioMed has higher earnings, but lower revenue than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Butterfly Network had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 3 mentions for Butterfly Network and 2 mentions for Orchestra BioMed. Butterfly Network's average media sentiment score of 0.61 beat Orchestra BioMed's score of 0.37 indicating that Butterfly Network is being referred to more favorably in the news media.
Orchestra BioMed currently has a consensus price target of $15.40, suggesting a potential upside of 250.00%. Butterfly Network has a consensus price target of $3.00, suggesting a potential upside of 27.39%. Given Orchestra BioMed's higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Butterfly Network.
Orchestra BioMed received 7 more outperform votes than Butterfly Network when rated by MarketBeat users. Likewise, 100.00% of users gave Orchestra BioMed an outperform vote while only 70.00% of users gave Butterfly Network an outperform vote.
53.5% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 37.8% of Butterfly Network shares are owned by institutional investors. 6.7% of Orchestra BioMed shares are owned by insiders. Comparatively, 27.3% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Butterfly Network has a net margin of -129.25% compared to Orchestra BioMed's net margin of -2,179.33%. Butterfly Network's return on equity of -42.68% beat Orchestra BioMed's return on equity.
Summary
Butterfly Network beats Orchestra BioMed on 9 of the 17 factors compared between the two stocks.
Get Orchestra BioMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Orchestra BioMed Competitors List
Related Companies and Tools
This page (NASDAQ:OBIO) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy OBIO Stock Free OBIO Stock Alerts